Taysha Gene Therapies, Inc.
No enriched coverage for $TSHA in the last 7 days.
No SEC Form 4 filings for $TSHA in the last 30 days.
See all $TSHA insider activity →Taysha Gene Therapies (TSHA) granted 384,000 RSUs and options for 92,400 shares to four new employees under Nasdaq Rule 5635(c)(4). RSUs vest over four years, and the stock options have a $4.74 exercise price, vesting over four years with a 10-year term. TSHA focuses on AAV-based gene therapies for severe CNS diseases, with its lead program TSHA-102 targeting Rett syndrome.
Red Cat (RCAT) analysts predict 115% upside to $18 per share despite rising expenses. Taysha (TSHA) advances TSHA-102 for Rett syndrome, awaiting FDA application. Solaris (SLSR) eyes 118% gain if Warintza copper project succeeds, pending feasibility study.
Taysha Gene Therapies (TSHA) reported Q2 2026 earnings, with a net loss of $46.6M, up from $26.9M in the prior year. R&D expenses rose to $38.6M, and cash reserves totaled $455.4M. The company completed dosing in REVEAL and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with 100% of Part A patients meeting responder status. Management expects regulatory discussions in H1 2027 and extended cash runway into H2 2028.
Recent TSHA coverage spans corporate actions, financial news and earnings.
The compensation grant is a routine corporate action with limited market impact.
Clinical progress could spark significant move if data are positive.
Clinical and regulatory path progress plus a large cash raise increases near-term visibility for a BLA submission timeline.
The earnings miss and larger net loss shift near-term focus to cash burn and runway ahead of 2027 BLA-enabling milestones.
The filing adds concrete clinical and regulatory timing catalysts (6-month interim analysis basis for BLA, FDA feedback in 1H 2027) plus cash runway extension via a $230M follow-on.
AlphAI scores every news story that mentions TSHA with an AI model for sentiment and relevance, and aggregates insider trades from Taysha Gene Therapies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Taysha Gene Therapies (TSHA) granted 384,000 RSUs and options for 92,400 shares to four new employees under Nasdaq Rule 5635(c)(4). RSUs vest over four years, and the stock options have a $4.74 exercise price, vesting over four years with a 10-year term. TSHA focuses on AAV-based gene therapies for severe CNS diseases, with its lead program TSHA-102 targeting Rett syndrome.
1 min readRed Cat (RCAT) analysts predict 115% upside to $18 per share despite rising expenses. Taysha (TSHA) advances TSHA-102 for Rett syndrome, awaiting FDA application. Solaris (SLSR) eyes 118% gain if Warintza copper project succeeds, pending feasibility study.
2 min readTaysha Gene Therapies (TSHA) reported Q2 2026 earnings, with a net loss of $46.6M, up from $26.9M in the prior year. R&D expenses rose to $38.6M, and cash reserves totaled $455.4M. The company completed dosing in REVEAL and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with 100% of Part A patients meeting responder status. Management expects regulatory discussions in H1 2027 and extended cash runway into H2 2028.
6 min readTaysha Gene Therapies (TSHA) shares fell 7% after the company reported a wider-than-expected Q2 loss. EPS was -$0.13 vs -$0.12 consensus, and net loss rose to $46.6M from $26.9M a year earlier, driven by higher R&D and G&A. Cash totaled $455.4M after a June 2026 follow-on financing.
3 min readTaysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis
6 min readTaysha Gene Therapies (NASDAQ:TSHA) priced an underwritten public offering of 32.5M shares at $6 each on June 24, plus prepaid warrants for 833,333 shares at $5.999 per warrant. The company expects about $200M gross proceeds and a 30-day option for up to 5M more shares. Bank of America raised its TSHA target to $10 from $9 and reiterated Buy after Part A REVEAL Rett syndrome study updates.
4 min readTaysha Gene Therapies said its R&D chief sold about $1.2 million of stock under a 10b5-1 plan, after a 149% share run. The executive still holds 936,410 shares. The company also reaffirmed FDA alignment for TSHA-102’s BLA pathway, citing REVEAL trial dosing completion of 17 patients and early durable results, with $276.6 million cash into 2028.
4 min readNagendran Sukumar (President and Head of R&D) sold 200,000 shares of Taysha Gene Therapies, Inc. (TSHA) at $6.24 ($1.25M total) on 2026-07-10 under a Rule 10b5-1 trading plan.
1 min readTaysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d121397dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Taysha Gene Therapies, Inc. Common Stock Pre-Funded Warrants Underwriting Agreement June 24, 2026 Jefferies LLC Goldman Sachs & Co. LLC As representatives of the several Underwriters named in Schedule I hereto c/o Jefferies LLC
4 min readTaysha Gene Therapies, Inc. (NASDAQ: TSHA) has announced the agenda for its annual stockholder meeting on June 1, 2026, which includes voting on the election of two Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and a non-binding advisory vote on executive compensation. Stockholders will also decide the preferred frequency for future "say-on-pay" votes. The proxy statement details executive compensation for 2025, with CEO Sean Nolan receiving over $4 million, and lists major beneficial owners.
3 min read
